Bazedoxifene is a selective estrogen receptor modulator used to manage osteoporosis in postmenopausal women. Osteoporosis is characterized by the gradual decline in overall bone density that exposes patients to an increased risk of proximal fractures. Approved by the U.S. Food and Drug Administration (FDA) as a combination drug alongside conjugated estrogens, bazedoxifene is crucial in addressing vasomotor symptoms associated with menopause and preventing postmenopausal osteoporosis. This activity explores the approved indications, mechanisms of action, proper administration, potential adverse events, and contraindications of bazedoxifene. Participants gain insights to deliver optimal care to high-risk women with osteoporosis and associated menopausal symptoms, especially in cases where conventional therapies are contraindicated.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/148093
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Chemical Pathology, Complex General Surgical Oncology, Endocrinology, Diabetes, and Metabolism, Geriatric Medicine, Hospital Medicine, Internal Medicine, Medical Oncology, Rheumatology